bioAffinity Technologies, Inc. (BIAF): Entry into a Material Definitive Agreement
bioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 7 ex10-1.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “ Agreement ”) is made and entered into effective as of August 12, 2026, between BIOAFFINITY TECHNOLOGIES, INC., a Delaware corporation (the “ Company ”), and each pur
How this was made
The 30-second read
Why it matters
This is a primary-source disclosure of a new financing arrangement. The market impact will depend on the final deal size and dilution profile, which are not present in the provided excerpt.
Market read
A new equity-linked financing disclosure can quickly change expectations for dilution and runway, driving trading volatility around the next open.
What to watch
Traders will need the missing exhibit details: total subscription amount, security mix, warrant strike/exercise mechanics, any escrow/closing conditions, and whether proceeds fund near-term clinical or regulatory milestones.
Background
The 8-K reports entry into a material definitive agreement and unregistered sales of equity securities, with Exhibit 10.1 containing the securities purchase agreement.
Ticker impact
bioAffinity Technologies entered a material definitive securities purchase agreement, disclosed via SEC 8-K Item 1.01 and Exhibit 10.1.
Near-term downside risk from dilution expectations, with volatility likely until final pricing, size, and warrant terms are confirmed in the full exhibit.
The article is an SEC 8-K for a securities purchase agreement and unregistered equity issuance, but the provided excerpt does not include the key economic terms (gross proceeds, share/warrant counts, exercise price, closing conditions).
Market effects
Adds another example of equity-linked financing in small-cap biotech, which can modestly affect sentiment toward similarly capital-constrained issuers.
Limited, primarily US microcap sentiment.
Low, company-specific capital raise disclosure.
Counterpoint
If the financing is structured with favorable terms (e.g., limited dilution, strong warrant coverage economics, or strategic investors), the market may re-rate the balance-sheet outlook rather than sell off.
Key entities
- issuerbioAffinity Technologies, Inc.
Delaware corporation filing the 8-K for a securities purchase agreement and unregistered equity issuance.
- counterpartiesPurchasers (unnamed in excerpt)
Investors identified on the signature pages to the securities purchase agreement.
- regulatorSEC
Referenced as the Commission for registration and resale mechanics.
